Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Coco-scalp, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Southeast Asia and the Rest of the world. It generates the majority of the revenue from Australia whichincludes the sales and distribution activity relating to the Australian market.
|26 Nov 2021||$4.56||$-0.12||-2.56%||3,676||$4.65||$4.65||$4.56|
|25 Nov 2021||$4.68||$0.05||1.08%||1||$4.68||$4.68||$4.68|
|22 Nov 2021||$4.63||$-0.17||-3.54%||5,548||$4.65||$4.65||$4.63|
|19 Nov 2021||$4.80||$0.05||1.05%||4,242||$4.80||$4.80||$4.80|
|18 Nov 2021||$4.75||$0.17||3.71%||4,317||$4.74||$4.75||$4.74|
|17 Nov 2021||$4.58||$0.08||1.78%||566||$4.50||$4.58||$4.50|
|16 Nov 2021||$4.50||$0.00||0.00%||3||$4.50||$4.50||$4.50|
|15 Nov 2021||$4.50||$0.00||0.00%||217||$4.60||$4.60||$4.50|
|12 Nov 2021||$4.50||$0.00||0.00%||200||$4.50||$4.50||$4.50|
|11 Nov 2021||$4.50||$-0.22||-4.66%||305||$4.50||$4.50||$4.50|
|09 Nov 2021||$4.72||$0.39||9.01%||216||$4.59||$4.72||$4.59|
|08 Nov 2021||$4.33||$0.01||0.23%||2||$4.33||$4.33||$4.33|
|04 Nov 2021||$4.32||$0.12||2.86%||3,589||$4.32||$4.43||$4.32|
|Mr Jon Lamb||Non-Executive Director||Sep 2012||
Mr Lamb has led the planning, marketing and restructuring of companies throughout his career. He has held roles at Beecham including CEO in New Zealand and Marketing Manager in both Australia and South Africa. He has also held roles as CEO of Nylex in New Zealand, Managing Director within the Rural Division of Fletcher Challenge, Director of Southland Frozen Meats and Marketing Director of the New Zealand Kiwifruit Marketing Board. He was a Director of Virionyx, a New Zealand company that developed an antiviral drug designed to combat AIDS. He was Deputy Chair of Australian diagnostic company ATF Group that developed a real time tool for measuring the Hepatitis B virus in individual patients. He serves as a director of Coronation Equities Limited, Culture Check Limited, Project X Trustee Limited, Three Dots Limited, Redvers Limited, Indica Industries NZ Limited, Medreleaf NZ Limited and was a director of Zoono Limited. He is also a trustee of Rivers One Limited. He serves as a chair of the Risk Committee.
|Mr David Mark Flacks||Non-Executive ChairmanNon-Executive Director||Jun 2015||
Mr Flacks is a director of a environmentally pro bono organisations. He is a former chair of the NZX Markets Disciplinary Tribunal and a former member of the Takeovers Panel. He is also a director of boutique corporate law firm Flacks & Wong. He was a senior corporate partner at Bell Gully and was general counsel and company secretary of Carter Holt Harvey during the 1990's. He is also chair of the Regulatory Governance Committee of the NZX, chair of the Suncorp NZ group of companies, Harmoney Corp Limited, Upside Biotechnologies Limited. He is a director of Vero Insurance New Zealand Limited, Vero Liability Insurance New Zealand Limited Asteron Life Limited. He was a director of NZ Venture Investment Fund. He is a member of the Risk Committee.
|Dr John Douglas Wilson||Non-Executive Director||Sep 2012||
Dr Wilson was an Associate Professor at the Auckland Medical School before taking a role as Senior Vice President and Head of Medicine and Regulatory Affairs in the US for German drug company Boehringer Ingelheim Pharmaceuticals. He then carried these same responsibilities to Boehringer's worldwide medical research group in Germany, overseeing all research and drug development programmes. He supervised sixteen drugs to the US market through FDA and others into global markets. He has been a consultant to pharmaceutical and biotech companies in New Zealand, Australia, Italy, the UK, Ireland and New York. He was a consultant of Ferghana Partners Inc. He has been a director of Neuren Pharmaceuticals, of a drug discovery company Phylogica in Perth Australia, and of Adherium - a medical device company. He is currently a consultant to the Ryman Healthcare clinical governance committee. He is a director of Mainz Consulting Limited. He is also a member of Commercial Committee at Malaghan Institute. He is a chairman of Regulatory and Product Development Oversight Committee.
|Ms Marree Atkinson||Chief of StaffManaging Director||Sep 2012||
Ms Atkinson has held roles in sales, regulatory affairs, customer services and logistics. She is a registered nurse previously practising at Waikato Hospital.
|Mr Hartley Atkinson||FounderChief Executive OfficerExecutive Director||Sep 1997||
Mr Atkinson worked at Swiss multinational pharmaceutical company, Roche, for eight years where he held positions as Sales & Marketing Director, Medical Director, Product Manager and Medical Manager. Prior to his work at Roche, he was a Drug Information Pharmacist and Researcher at the Department of Clinical Pharmacology, Christchurch Hospital. He is the author of a of scientific publications. His work has been published in the - The New England Journal of Medicine.
|Mr James (Jim) Burns||Non-Executive Director||Sep 2015||
Mr Burns has executive experience in pharmaceuticals, biotechnology, medical devices, and diagnostics. He has served in leadership roles at multinational corporations, early-stage companies, venture capital funds and private equity. From 2009-2016, he served as Chairman of the Board, Executive Chairman and Chief Executive Officer of Assurex Health, a precision medicine company focused on neuropsychiatric and pain disorders. Previous roles include President & CEO of cancer drug development company CASI Pharmaceuticals; President of MedPointe Pharmaceuticals, a specialty pharmaceutical company; President & CEO of biotechnology company Osiris Therapeutics; General Partner of Healthcare Ventures; Group President of Becton Dickinson, a global medical device company; and Partner at Booz & Company, an international consulting firm. He is a director of Director of Vermillion, Inc., Precera Bioscience Inc., and VisionGate Inc. He is also a director and executive chairman of Phenomics Health Inc. He is a member of the Risk Committee.
|Ms Anita Baldauf||Non-Executive Director||Nov 2020||
Ms Baldauf has experience in international business development, finance, compliance, personnel development and governance through her 22-year career with Nestle. More recently she has been advising New Zealand start-ups and new ventures as they navigate through the challenges of growth and changing market environments. Ms Baldauf, who is also a fellow of the Edmund Hillary Fellowship.
|Dr Ted Witek||Non-Executive Director||Jan 2021||
Dr Witek has more than three decades of international clinical development and leadership experience. Between 2014 and 2018 Dr Witek served as Senior Vice President, Corporate Partnerships, and Chief Scientific Officer at Innoviva in San Francisco. Prior to that he spent more than two decades, mainly in the US, with Boehringer Ingelheim where he rose to the role of President and CEO of the multi-national's Canadian and Portuguese operations. He has served on the boards of numerous professional societies including the Board of Directors of Canada's Research-Based Pharmaceutical Companies (Rx&D) and the Drug/Device Discovery and Development Committee of the American Thoracic Society. He has also served on the boards of numerous advisory organisations and companies including the Government of Ontario Health Innovation Council, Columbia University Health and Innovation Technology Lab, Lumira Ventures and Trudell Medical International. He has also authored more than 100 scientific publications in the fields of respiratory health, public health, airway disease, and drug development and is a reviewer for numerous scientific journals.
|Mr Malcolm Tubby||Chief Financial OfficerCompany Secretary||
|Malcolm Tubby||Chief Financial OfficerCompany Secretary||
|Hartley Atkinson & Colin Mckay||72,899,435||69.66%|
|Accident Compensation Corporation Nzcsd||4,379,184||4.18%|
|FNZ Custodians Limited||2,599,493||2.48%|
|Forsyth Barr Custodians Limited||2,125,725||2.03%|
|BNP Paribas Nominees (Nz) Limited - Nzscd||1,930,087||1.84%|
|Citicorp Nominees Pty Limited||1,094,231||1.05%|
|HSBC Nominees (New Zealand) - Nzcsd||932,220||0.89%|
|HSBC Nominees A/C Nz Superannuation Fund Nominees Limited Nzcsd||854,404||0.82%|
|Tea Custodians Limited Client Property Trust Account Nzcsd||763,023||0.73%|
|New Zealand Depository Nominee Limited||692,299||0.66%|
|BNP Paribas Nominees (Nz) Limited Nzscd I||651,770||0.62%|
|Jp Morgan Nominees Australia Limited||529,815||0.51%|
|FNZ Custodians Limited I||502,990||0.48%|
|Cs Third Nominees Pty Limited||344,761||0.33%|
|Custodial Services Limited||297,000||0.28%|
|Rivers One Limited||221,305||0.21%|
|Hamish Stewart Atkinson & Karen Winifred Atkinson & Andrew John Marriott||203,333||0.19%|
|FNZ Custodians Limited II||203,253||0.19%|
|BNP Paribas Nominees (Nz) Limited Nzscd||199,283||0.19%|